tradingkey.logo

Smith & Nephew PLC

SNN

37.450USD

+0.230+0.62%
Close 08/29, 16:00ETQuotes delayed by 15 min
16.40BMarket Cap
--P/E TTM

Smith & Nephew PLC

37.450

+0.230+0.62%

TradingKey Stock Score

Financial Health

Valuation Dimension

Forecast

Momentum

Institutional Confidence

Risk Assessment

Peers

TradingKey Stock Score

Financial Health

Valuation Dimension

Forecast

Momentum

Institutional Confidence

Risk Assessment

Peers

TradingKey Stock Score

Currency: USD Updated2025-08-29

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
154 / 280
Overall Ranking
361 / 4751
Industry
Healthcare Services & Equipment

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analysts' Target

Based on 5 analysts
Buy
Current Rating
35.157
Target Price
-6.12%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 84.75.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 79.37%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 79.37%.
Overvalued
The company’s latest PE is 33.32, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 34.86M shares, decreasing 25.88% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 1.60M shares of this stock.

Financial Health

Currency: USD Updated2025-08-29

There is no financial score for this company; the Healthcare Services & Equipment industry's average is 7.15.

Score

Industry at a Glance

Previous score
0.00
Change
0

Financials

Related Indicators

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

Operational Efficiency

Growth Potential

Shareholder Returns

Valuation Dimension

Currency: USD Updated2025-08-29

The company’s current valuation score is 1.80, which is lower than the Healthcare Services & Equipment industry's average of 2.15. Its current P/E ratio is 33.14, which is -7.75% below the recent high of 30.58 and 17.78% above the recent low of 27.25.

Score

Industry at a Glance

Previous score
2.60
Change
-0.8

Valuation Dimension

P/E

P/B

P/S

P/CF

Industry Ranking 154/280
No Data

Forecast

Currency: USD Updated2025-08-29

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Services & Equipment industry's average of 7.66. The average price target for Smith & Nephew PLC is 36.75, with a high of 41.00 and a low of 26.13.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts
Buy
Current Rating
35.157
Target Price
-6.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

117
Total
7
Median
9
Average
Company name
Ratings
Analysts
Smith & Nephew PLC
SNN
5
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
28
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Momentum

Currency: USD Updated2025-08-29

The company’s current price momentum score is 9.74, which is higher than the Healthcare Services & Equipment industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 39.82 and the support level at 32.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.67
Change
0.05

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-0.220
Neutral
RSI(14)
71.404
Buy
STOCH(KDJ)(9,3,3)
78.326
Neutral
ATR(14)
0.455
High Vlolatility
CCI(14)
75.379
Neutral
Williams %R
12.048
Overbought
TRIX(12,20)
0.696
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
37.276
Buy
MA10
37.142
Buy
MA20
36.360
Buy
MA50
32.782
Buy
MA100
30.430
Buy
MA200
28.314
Buy

Institutional Confidence

Currency: USD Updated2025-08-29

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Services & Equipment industry's average of 7.19. The latest institutional shareholding proportion is 7.96%, representing a quarter-over-quarter increase of 7.90%. The largest institutional shareholder is Brandes Investmen, holding a total of 1.60M shares, representing 0.37% of shares outstanding, with 17.99% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BMO Capital Markets (US)
575.25K
+1338.13%
River Road Asset Management, LLC
2.91M
+43.17%
Scharf Investments, LLC
2.08M
-21.09%
Brandes Investment Partners, L.P.
Star Investors
1.54M
+13.03%
Goldman Sachs Asset Management, L.P.
1.09M
+22.41%
Goldman Sachs International
664.78K
+165.91%
Parametric Portfolio Associates LLC
972.81K
-26.29%
Barrow Hanley Global Investors
Star Investors
855.23K
-59.36%
1
2

Risk Assessment

Currency: USD Updated2025-08-29

The company's beta value is 0.73. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.71
Change
0.01
Beta vs S&P 500 index
0.75
VaR
+2.64%
240-Day Maximum Drawdown
+24.18%
240-Day Volatility
+32.31%
Return
Best Daily Return
60 days
+15.23%
120 days
+15.23%
5 years
+15.23%
Worst Daily Return
60 days
-2.54%
120 days
-5.83%
5 years
-13.03%
Sharpe Ratio
60 days
+2.97
120 days
+1.72
5 years
+0.18
Risk Assessment
Maximum Drawdown
240 days
+24.18%
3 years
+34.10%
5 years
+53.04%
Return-to-Drawdown Ratio
240 days
+0.78
3 years
+0.64
5 years
-0.02
Skewness
240 days
+0.65
3 years
+0.61
5 years
+0.20
Volatility
Realised Volatility
240 days
+32.31%
5 years
+27.72%
Standardised True Range
240 days
+1.47%
5 years
+1.59%
Downside Risk-Adjusted Return
120 days
+322.11%
240 days
+322.11%
Maximum Daily Upside Volatility
60 days
+36.92%
Maximum Daily Downside Volatility
60 days
+32.37%
Liquidity
Average Turnover Rate
60 days
+0.11%
120 days
+0.10%
5 years
--
Turnover Deviation
20 days
-2.29%
60 days
+3.50%
120 days
-3.35%

Peers

Currency: USD Updated2025-08-29
Smith & Nephew PLC
Smith & Nephew PLC
SNN
4.69 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.89 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Merit Medical Systems Inc
Merit Medical Systems Inc
MMSI
7.76 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Tenet Healthcare Corp
Tenet Healthcare Corp
THC
7.66 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Brightspring Health Services Inc
Brightspring Health Services Inc
BTSG
7.65 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
7.64 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.

KeyAI